3 articles
The UK's NICE has approved AstraZeneca and Daiichi Sankyo's breast cancer drug Enhertu for NHS use in England, expanding access to approximately 1,000 patients annually following revised cost-effectiv
IHH Healthcare confirmed an Indian court ordered a forensic audit into shareholding dissipation in Fortis Healthcare following a dispute with Daiichi Sankyo. The inquiry examines the transaction where
AstraZeneca and Daiichi Sankyo are nearing a pricing agreement with UK regulators for their breast cancer drug Enhertu following a previous coverage denial. Talks aim to secure reimbursement access wh
ChemBrief